The Gabriella Miller Kids First Pediatric Research Program (Kids First) is pleased to announce a series of new releases for its publicly available data in childhood cancer. These recent releases were added to the program’s Data Resource Center collaborative pediatric research effort and are accompanied by a series of data and program updates. 

The Kids First program is excited to announce a number of recent public data releases for use among the program’s pediatric cancer research community. These public data releases include:

• On September 26, 2022, Gabriella Miller Kids First Pediatric Research Program released data on Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL). The primary goal in the treatment of T-ALL is to prevent relapse, which requires accurate risk stratification. No genetic alterations have been identified to date that reproducibly predict relapse independent of residual disease. Research led by Dr. David T. Teachey of the Children’s Hospital of Philadelphia involved the selection of approximately 1,350 cases of T-ALL from children and young adults treated through a clinical trial. These cases were submitted for sequencing of tumor DNA and RNA and original patient DNA. This included: whole genome sequencing, whole exome sequencing, and transcriptome profiling of tumor DNA/RNA and whole genome sequencing of germline DNA. Read more about the clinical trial.

Updates to Existing Data Releases

• Effective October 6, 2022, the NICHD GMKF Enchondromatoses Study has been updated to version 2 in the dbGaP system. The public study report page may be browsed at dbGaP.
• Effective October 21, 2022, the NCI GMKF Kidney UT Malformations Study has been updated to version 2 in the dbGaP system. The public study report page and summary-level phenotype data may be browsed at dbGaP.

The Gabriella Miller Kids First Pediatric Research Program looks forward to a number of additional releases in the near future.  To learn more about Kids First previously Funded Research, visit the program website.